These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35296994)

  • 21. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.
    Chen Q; Sun Q; Zhang J; Li B; Feng Q; Liu J
    PLoS One; 2024; 19(3):e0295090. PubMed ID: 38437209
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atezolizumab and Bevacizumab Targeted-Therapy in Advanced Hepatocellular Carcinoma: A Systematic Review of Cost-effectiveness Analyses.
    Mohammadnezhad G; Esmaily H; Talebi M; Jafari M
    J Gastrointest Cancer; 2024 Jun; 55(2):625-637. PubMed ID: 38488933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib.
    Gao J; Liu S; Li SJ; Wang R; Meng ZH; Kong XS
    Med Sci Monit; 2024 Jul; 30():e944526. PubMed ID: 39033318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
    Shu Y; Tang Y; Ding Y; Zhang Q
    Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma.
    Dai L; Cai X; Mugaanyi J; Liu Y; Mao S; Lu C; Lu C
    Sci Rep; 2021 Oct; 11(1):19711. PubMed ID: 34611195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
    Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
    J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France.
    Gaugain L; Cawston H; Dubois de Gennes C; Sanchez Alvares J; Nahon P; Mazaleyrat B; Le Dissez C
    PLoS One; 2023; 18(1):e0280442. PubMed ID: 36652428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):e6904. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of first-line versus second-line use of domestic anti-PD-1 antibody sintilimab in Chinese patients with advanced or metastatic squamous non-small cell lung cancer.
    Cheng R; Zhou Z; Liu Q
    Cancer Med; 2023 Mar; 12(6):7389-7397. PubMed ID: 36373001
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Li Y; Liang X; Li H; Chen X
    Cancer; 2022 Nov; 128(22):3995-4003. PubMed ID: 36111952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
    Zheng Z; Lin Y; Cai H
    Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma.
    Tseng CY; Tsai YW; Shiu MN
    Front Oncol; 2023; 13():1264417. PubMed ID: 38023232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
    Shao T; Zhao M; Tang W
    Front Oncol; 2022; 12():953671. PubMed ID: 36561521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
    Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
    PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
    Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
    J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-Effectiveness of Donafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.
    Guan H; Wang C; Zhao Z; Han S
    Adv Ther; 2022 Jul; 39(7):3334-3346. PubMed ID: 35644019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma.
    Zeng X; Jia Y; Chen H; Luo Q; Zhao H; Liang G; Chen W; Li Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9213-9219. PubMed ID: 37188985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China.
    Li W; Wan L
    Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; 24(5):671-678. PubMed ID: 38594905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.